Top Page
Cadrenal Therapeutics, Inc.
(NASDAQ:CVKD)
Cadrenal Therapeutics, Inc. (CVKD) vs. SPDR S&P 500 ETF (SPY)
Cadrenal Therapeutics, Inc. Business Overview & Revenue Model
Cadrenal Therapeutics, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.92K | -1.88K | 0.00 | -1.27K |
| EBITDA | -14.45M | -10.65M | -8.34M | -6.61M |
| Net Income | -14.39M | -10.65M | -8.36M | -6.71M |
Balance Sheet | ||||
| Total Assets | 4.09M | 10.12M | 8.52M | 778.17K |
| Cash, Cash Equivalents and Short-Term Investments | 3.86M | 10.02M | 8.40M | 32.59K |
| Total Debt | 0.00 | 0.00 | 21.35K | 640.71K |
| Total Liabilities | 1.35M | 2.68M | 826.88K | 6.33M |
| Stockholders Equity | 2.73M | 7.44M | 7.69M | -5.55M |
Cash Flow | ||||
| Free Cash Flow | -11.83M | -7.36M | -3.53M | -1.20M |
| Operating Cash Flow | -11.82M | -7.36M | -3.53M | -1.20M |
| Investing Cash Flow | -11.64K | -6.54K | -3.25K | -2.28K |
| Financing Cash Flow | 11.33M | 8.98M | 11.90M | 1.24M |
Cadrenal Therapeutics, Inc. Technical Analysis
Cadrenal Therapeutics, Inc. Risk Analysis
Cadrenal Therapeutics, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $28.29M | -4.69 | ― | ― | ― | ― | |
46 Neutral | $18.42M | -0.98 | -468.03% | ― | ― | -9.80% | |
44 Neutral | $19.36M | -0.02 | -565.18% | ― | -48.74% | 89.18% | |
38 Underperform | $18.31M | -1.41 | -92.74% | ― | 280.77% | 32.82% |
Cadrenal Therapeutics, Inc. Corporate Events
On December 23, 2025, Cadrenal Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to continue using its at-the-market equity offering program, allowing the company to offer and sell up to an additional $1,770,028 of its common stock through H.C. Wainwright & Co. as sales agent. This supplemental capacity, which follows approximately $10.0 million of stock already sold under the existing March 11, 2024 agreement, provides Cadrenal with flexible, discretionary access to incremental capital, while specifying parameters such as trading periods, volume limits, and minimum prices, and compensating H.C. Wainwright with a 3% fee on gross sales, with no obligation for the company to sell any shares and the ability for either party to terminate the arrangement under agreed conditions.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
On December 15, 2025, Cadrenal Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 207,374 shares of common stock and unregistered warrants to purchase up to 414,748 shares, aiming to raise approximately $2.2 million. The offering, expected to close on December 16, 2025, includes a lock-up period and restrictions on further stock issuance, impacting the company’s financial strategy and market operations.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
On December 10, 2025, Cadrenal Therapeutics acquired VLX-1005 and related assets from Veralox Therapeutics, enhancing its pipeline with a first-in-class drug candidate targeting immune signaling pathways in HIT. This acquisition, announced on December 11, 2025, positions Cadrenal to address the $40 billion global anticoagulation market and the $1 billion HIT market in the US and EU. VLX-1005, which has received Orphan Drug and Fast Track designations from the FDA, has shown promising results in Phase 1 and Phase 2 studies, potentially improving patient outcomes. The acquisition agreement includes upfront and milestone payments to Veralox, along with royalties on future global sales, enabling Cadrenal to focus on advancing VLX-1005’s clinical development.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
On December 1, 2025, Cadrenal Therapeutics announced the appointment of Dr. Lee Scott Golden to its Board of Directors. Dr. Golden brings over 25 years of experience in clinical development, particularly in cardiovascular medicine and anticoagulation, aligning with the company’s mission to advance safer anticoagulant options. His expertise is expected to guide Cadrenal’s strategy and clinical programs, potentially enhancing its industry positioning and value for shareholders.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
On November 18, 2025, Cadrenal Therapeutics, Inc. announced the filing of a prospectus supplement with the SEC for an ‘at the market offering’ program, allowing the sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co., LLC. This move follows the company’s previous sale of $9,386,964 in shares under the same agreement. The offering is conducted under a registration statement effective since March 2024, and the agreement allows for flexible sales parameters. The company retains the right to suspend or terminate the agreement, and Wainwright will receive a 3% commission on sales.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.